Introduction {#Sec1}
============

Whipple's disease (WD) is a rare, chronic, systemic infection caused by *Tropheryma whipplei*, a Gram-positive intracellular bacillus related to actinomycetes. WD is a rare infectious disease with protean clinical manifestations. WD may often manifest itself as chronic seronegative oligoarthritis or polyarthritis, which may mimic various joint diseases (rheumatoid arthritis or spondylarthritis). The organism may be detectable by periodic acid--Schiff (PAS) staining of affected organ tissue, especially small bowel, or with 16S ribosomal ribonucleic acid (rRNA) gene identification by polymerase chain reaction (PCR) amplification \[[@CR1], [@CR2]\].

Increased susceptibility to infections is a major safety concern with tumor necrosis factor alpha (TNF-α) antagonist treatment \[[@CR3]\]. Infection should be ruled out in atypical cases by searching for foci \[[@CR4]\]. Several authors have shown that treatment with TNF-α blockers seems to increase the risk of exacerbating WD \[[@CR5]\] or worsening preexisting WD, triggering visceral disorders \[[@CR4], [@CR6]\].

We describe two cases of patients who were given TNF-α antagonists to treat long-standing joint disease, who then experienced the involvement of several organs leading to the diagnosis of WD. We also review the case reports of WD diagnosed during anti-TNF-α treatment.

Case presentation {#Sec2}
=================

From 2000 to 2012, eight cases of WD were diagnosed at two Spanish hospitals (Hospital General Universitario de Alicante, Alicante and Hospital Marina Baixa, Villajoyosa, Alicante), and two cases were associated with use of TNF-α antagonists.

Case report 1 {#Sec3}
-------------

A 58-year-old white man with inflammatory back pain and large and small joint arthritis had been diagnosed with psoriatic spondylarthritis 9 years ago. Our patient had been treated with adalimumab for 4 months, after that with etarnecept for 8 months, then infliximab for 2 months, tocilizumab for 21 months and golimumab for 1 month, to treat the pain in his back and neck with the consequent difficulty in bending, and arthritis of his knee and interphalangeal joint arthritis. Our patient was admitted to the hospital with abdominal septic shock. A computed tomography (CT) scan showed multiple retroperitoneal lymph nodes. The colonoscopy result was normal and the biopsy result was normal. Three months later, he was admitted again with a fever and heart failure, which was interpreted as a side effect of the golimumab treatment. One year after that, he was admitted to the hospital with abdominal pain, diarrhea and weight loss progressing to a severe wasting syndrome. At this time, he was being treated with 5mg prednisone plus hydroxicloroquine and methotrexate (MTX). Abnormal laboratory test results included a white blood cell (WBC) count of 14,630/mm^3^, a hemoglobin level of 9.6g/dL and an erythrocyte sedimentation rate (ESR) of 58mm/h. A CT scan showed multiple lymph nodes. Endoscopy showed diffuse intestinal lymphangiectasia (Fig. [1](#Fig1){ref-type="fig"}). A duodenal biopsy showed distortion of the villous architecture with abundant macrophages, and bacilliform intracytoplasmic structures that stained positive with PAS with diastase digestion compatible with WD. A PCR assay for detecting *T. whipplei* was not done. Intravenous ceftriaxone (2g daily for 2 weeks) was commenced followed by trimethoprim and sulphamethoxazole with improved symptoms after 3 weeks; treatment was continued for 18 months. One year later, a new gastroscopy with duodenal biopsy was done. It did not show intestinal lymphangiectasia. A PCR assay result for *T. whipplei* was negative. There were no relapses after 19 months.Fig. 1Endoscopy. White lesions compatible with diffuse intestinal lymphangiectasia

Case report 2 {#Sec4}
-------------

A 73-year-old white man had been diagnosed with rheumatoid arthritis with migratory arthralgias of the large joints and chronic obstructive pulmonary disease 14 years ago. Our patient had been treated with gold salts, chloroquine and MTX. Fourteen years after diagnosis of his diseases, infliximab was added to the MTX treatment without improvement, so infliximab was suspended 8 months later because there was no improvement of his migratory nondeforming polyarthritis; treatment with MTX was continued. After 5 months infliximab was stopped, and etanercept was added to MTX for 6 months. During treatment with etanercept, he suffered an acute middle cerebral artery ischemic stroke of atherothrombotic origin, and etanercept was stopped. Six months later, rituximab was added for 3 months, without improvement. After that, MTX was stopped and leflunomide (20mg/day) was initiated and from that point, our patient presented with abdominal pain, chronic diarrhea and edema in his lower extremities, a consequence of chronic malabsorption. After 1 year on this treatment, he was admitted to hospital with rectal bleeding, however, the colonoscopy and gastroscopy results were normal and the colon biopsy showed unspecific changes. At that time, our patient was being treated with leflunomide, which was then stopped. Three months after that admission, our patient was admitted with weight loss, abdominal pain and diarrhea. On physical examination, he had hyperpigmentation of the skin but no other abnormalities. Abnormal laboratory test results included a WBC count of 13,800/mm^3^, a hemoglobin level of 9.2g/dL, mean corpuscular volume (MCV) of 72fl, an albumin level of 1.8g/dL, and an ESR of 13mm/h. A thoracic and abdominal CT scan showed pericardial effusion with calcifications, bronchiectasis in his lower right lung, intestinal bowel with distention and no abdominal lymph nodes. A duodenal biopsy showed altered architecture and intracellular bacilli on PAS stain. *T. whipplei* was detected from duodenal tissue by PCR assay. A cerebral magnetic resonance imaging scan showed multiple hyperintensive lesions in both cerebral hemispheres, cortical retraction, increased subarachnoid space and ventricular dilatation. The PCR assay result for *T. whipplei* in his cerebrospinal fluid was negative. Intravenous ceftriaxone (2g daily) was commenced for 2 weeks followed by trimethoprim and sulphamethoxazole with improvement of his symptoms (the diarrhea, malabsorption and pericardial effusion). One year later, a new gastroscopy with duodenal biopsy was done. It showed altered architecture and intracellular bacilli on PAS stain, but the PCR assay result for *T. whipplei* was negative. Because of mild renal failure, trimethoprim and sulphamethoxazole was changed for doxycycline plus hydroxychloroquine, and normal renal function was recovered.

Discussion {#Sec5}
==========

We reviewed database cases recorded in PubMed using the following retrieval scheme: \["Whipple disease" and ("infliximab" or "adalimumab" or "etanercept" or "golimumab" or "tocilizumab")\]. We gathered the following data from the medical cases reported: age, sex, joint diseases, years with joint disease, TNF-α antagonist therapy, days with TNF-α antagonist therapy before WD was diagnosed, symptoms related to WD, organs affected by WD, investigations for diagnosing WD, treatment and outcome of WD.

We retrieved 14 cases from the PubMed database from January 2004 to December 2014. All the case reports recorded and the two case reports in this manuscript are from European scientists \[[@CR4]--[@CR10]\], except one case from the United States of America \[[@CR11]\]. Four case reports were published in a language other than English \[[@CR7], [@CR8], [@CR10]\]. Table [1](#Tab1){ref-type="table"} shows age, sex, joint diseases, years with joint disease, TNF-α antagonist therapy, days with TNF-α antagonist therapy before WD was diagnosed, symptoms related to WD, organs affected by WD, investigations for diagnosing WD, treatment and outcome of WD for 16 WD cases. Out of 16 cases, there were 14 men and two women patients with an age range of 33 to 73 years old. Six patients were diagnosed as ankylosis spondylitis (AS), six as seronegative spondyloarthropathy (SA) (seronegative chronic polyarthritis), two as rheumatoid arthritis (RA), one as Still's disease (SD), and one as psoriatic arthritis. All patients had osteoarticular (with pain and swelling) involvement and 15 had gastrointestinal involvement (diarrhea, weight loss, abdominal pain, malabsorption, and so on) \[[@CR4]--[@CR12]\]. Moreover, some patients had extra-articular and gastrointestinal involvement, such as vertebra \[[@CR5]\], meningitis \[[@CR6]\], pericarditis (\[[@CR6]\], present report 2 (PR2)), abdominal or thoracic lymph nodes (\[[@CR4], [@CR6]\], PR1), gingiva such as scurvy \[[@CR9]\] and heart valve involvement \[[@CR10]\]. All were diagnosed by histological biopsy, in 14 of 15 cases a PCR assay for DNA detection of *T. whipplei* was done, and all were positive. The DNA of *T. whipplei* by PCR assay was detected in duodenal or other gastrointestinal-colonic areas; saliva, blood, feces, bone or cerebrospinal fluid \[[@CR4]--[@CR11]\]. All patients recovered from gastrointestinal involvement when the TNF-α antagonist was stopped and antibiotic treatment was started.Table 1Features of the patients' diagnosis of Whipple's disease after tumor necrosis factor alpha antagonist initiationAuthors / country / language of publicationAge / sexUnderlying disease previous WD diagnosis / time with that diagnosisTNF-α drugs and immunosuppressive treatmentStart of acute symptoms after TNF-α blockadeSymptoms after TNF-α blockadeOrgan involvementHistological diagnosis^a^Result of PCR for *Tropheryma whipplei*Treatment for WDOutcomeKneitz *et al*. (2005) \[[@CR4]\] / Germany / English34y / MSDMethotrexate + infliximab (2w)2wWeight loss, erythema nodosum, diarrhea, lymph node enlargement, and a sigmoidovesical fistulaSkin, gastroduodenitis and sigmoidovesicalPositive in fistula and lymph nodesPositive in lymph node, small bowel and sigmoidovesical fistulaSXT (12m)Resolved within 1 yearKremer *et al*. (2008) \[[@CR7]\] / Germany / German47y / MSA / 4yLeflunomide + adalimumabFever, weight loss, and severe arthralgiaPositive in duodenal tissuePositive in duodenal tissueSXTSpoerl *et al*. (2009) \[[@CR5]\] / Switzerland / English64y / MSA / 5 + 3yEtanercept4mLethargy, night sweats, weight lossGastrointestinal and vertebralPositive in duodenal tissue and vertebral tissuePositive in gastric and vertebral tissueCeftriaxone (2w), then, SXT (2y), (12m) then doxycycline + HC (18m)No relapses after 34-month follow-upAhmadi-Simab *et al*. (2009) \[[@CR8]\] / Germany / German33y / FAS / 8yEtanercept12mDiarrhea, abdominal pain and weight lossNegative in duodenal tissuePositive in duodenal biopsyCeftriaxone (2w) after SXTHoppé *et al*. (2010) \[[@CR6]\] / France / English67y / FSA / 7yInfliximab (4m)4mChest pain, dyspnea, polyarthritisPositive in duodenal tissuePositive in duodenal tissue. Negative in blood and salivaCeftriaxone (2w), then doxycycline (24m)Resolved within 15d. No relapses after 71-month follow-upHoppé *et al*. (2010) \[[@CR6]\] / France / English40y / MAS / 1yInfliximab (18m) then etanercept (7m) then adalimumab (1m)26mDiarrhea, weight loss, fever, arthralgiaWidespread ileocolitis, gastroduodenitis, meningitisPositive in duodenal tissuePositive in saliva, feces and cerebrospinal fluid. Negative in bloodDoxycycline, HC, and SXT (15d), then SXT was replaced by sulfasalazine 4g/dayResolved within 2 months. No relapses after 17-month follow-upHoppé *et al*. (2010) \[[@CR6]\] / France / English60y / MAS / 8yEtanercept (9m)9mFever, night sweats, polyarthritis, chest painPericarditis, mediastinal and abdominal lymphadenopathy, duodenitisNegative in duodenal tissuePositive in the duodenal sample, saliva, feces, and lymph nodesDoxycycline + HC (15m)Resolved within 7d. No relapses after 30-month follow-upHoppé *et al*. (2010) \[[@CR6]\] / France / English47y / MRA / 17yInfliximab (36m), then etanercept (42m), then adalimumab (6m), then rituximab, abatacept then infliximab (1m)85mFever, night sweats, weight loss, polyarthritis, radio carpal arthropathy. transient diplopia, myalgia, subacute depressionPericarditis, abdominal lymphadenopathy, duodenitisPositive PCR assay in the duodenal sample, blood, saliva, and feces. Negative PCR assay in cerebrospinal fluidDoxycycline + HC (UT)Resolved within 2m No relapses after 15-month follow-upHoppé *et al*. (2010) \[[@CR6]\] / France / English38y / MAS / 9yEtanercept (2m)9mDiarrhea, abdominal pain. weight loss, blurred visionHemorrhagic gastroduodenitis, hemorrhagic colitis, mediastinal and cervical lymphadenopathy, splenomegaly, meningitisPositive in duodenum and colonPositive PCR assay in blood, saliva, cerebrospinal fluid, and fecesDoxycycline 200mg/day. HC 600mg/day. (UT)Resolved within 3w. No relapses after 13-month follow-upHmamouchi *et al*. (2010) \[[@CR9]\] / France / English35y / MAS / 4yEtanercept4mGingival nodule, purpura, abdominal pain diarrhea, fatigue, weight lossGingiva and colitisPositive in colon tissuePositive in blood, stool, and cerebrospinal fluidSXT (NR)Resolved within 3 monthsDaïen *et al*. (2010) \[[@CR10]\] / France / English70y / MSA / 27yEtanercept (18m)NRFever and dyspneaEndocarditis of aortic valveNegative in duodenal tissue and, aortic valvePositive in aortic valveDoxycycline HC + SXT (18m)Resolved. No relapses after 21-month follow-upGaddy *et al*., (2012) \[[@CR12]\] / USA / English46y / MAS / 10yPrednisone + MTX + infliximab (24m), then adalimumab24mFever, migratory arthritis, weight loss, diarrheaGastroenteritisPositive in duodenal tissuePositive in blood and duodenal tissueCeftriaxone (x2w) after SXTNRSparsa *et al*. (2013) \[[@CR11]\] / France / French53y / MSAEtanercept (3m), then adalimumab (6m)9mPolyarthralgia peripheric, arthritis metarsophalangealPositive in duodenal tissue biopsyPositive in saliva and duodenal tissueDoxycycline + HC (18m)Resolved within 3 weeks. No relapses after 18-month follow-upSparsa *et al*. (2013) \[[@CR11]\] / France / French42y / MSA / 2mAdalimumab (9m) and then etanercept (4m)13mPolyarthralgia periphericPositive in duodenal and gastric tissuePositive in saliva and duodenal tissueDoxycycline + HC and then doxycycline aloneResolved within 3 weeks. No relapses after 17- month follow-upPresent report58y / MPsoriatic spondyloarthropathy/ 14yAdalimumab (4m), then etanercept (8m), infliximab (2m), tocilizumab (21m), golimumab (1m)36mAbdominal pain, diarrhea and weight lossDuodenitis and abdominal lymph nodesPositive in duodenal tissueNot doneCeftriaxone (14d), then SXT during (UT)Resolved within 3 weeks. No relapses after 9-month follow-up.Present report78y / MRA / 19yInfliximab (6m), etanercept (6m), rituximab (3m), leflunomide (24m)24mAbdominal pain, diarrhea and weight lossDuodenitis, and pericardial effusionPositive in duodenal tissuePositive in duodenal biopsy. Negative in cerebrospinal fluidCeftriaxone (14d), then SXT for (12m) then doxycycline + HCResolved within 3 weeks. No relapses after 18-month follow-up(UT) Patient still under treatment*TNF-α* tumor necrosis factor alpha, *WD* Whipple's disease, *PCR* polymerase chain reaction, *y* year, *SD* Still's disease, *w* week, *SXT* cotrimoxazole, *m* month, *SA* spondyloarthropathy (seronegative chronic polyarthritis), *HC* hydroxychlorochine, *AS* ankylosis spondylitis, *RA* rheumatoid arthritis, *NR* not reported, *MTX* methotrexate^a^Histological diagnosis = intracellular bacilli on periodic acid--Schiff stain

Conclusions {#Sec6}
===========

WD is a systemic infection, which involves many chronic manifestations, especially digestive disorders. Some of the manifestations involved are articular symptoms, which can appear as inflammatory rheumatism, such as rheumatoid arthritis or spondylarthritis. Beside these symptoms, the microorganism responsible for *T. whipplei* disease has also been found in DNA recovered from articular fluid and bones of these patients \[[@CR13], [@CR14]\].

Our two cases illustrate that alternative etiologies in patients with articular symptoms should be considered, most importantly following clinical deterioration by immunomodulatory agents like TNF-α inhibitors. The reflections to be made with respect to the analysis of these two cases are to speculate that these patients either had WD with mainly articular manifestations, which had been considered as a rheumatic disease; or in fact, they had a rheumatic disease, which, through the treatment with TNF drugs, may have reactivated *T. whipplei* and the appearance, therefore, of its florid symptoms that we managed to diagnose.

Therapies with immunomodulators, TNF-α inhibitors, and corticosteroids may transform an infection with *T. whipplei*, normally at a subacute stage, into a septic, life-threatening disease. Thus, it seems that TNF-α blockade allowed for rapid dissemination of *T. whipplei* by inhibiting some important immune defense mechanisms. In the later phase of an infection, the TNF-α blocker contributes to limiting the extent of cell and/or tissue damage by inducing apoptosis and maintaining granuloma formation \[[@CR15], [@CR16]\], which are important mechanisms in *T. whipplei* infections. TNF-α blockade might result in the loss of some of the immunological control mechanisms and, therefore, facilitate rapid bacterial dissemination and severe exacerbation of the disease. This is the situation in the first case.

In the second case, the TNF-α blockade was used before the gastrointestinal symptoms appeared. However, with anti-TNF-α treatment, our patient had an acute stroke. After stopping the treatment, our patient recovered from his central nervous system symptoms. When the gastrointestinal involvement of WD was discovered, an examination of DNA for *T. whipplei* was performed but it was negative. In this case, it was not clear that our patient had neurological involvement of WD, and real improvement of WD after stopping the TNF-α blockade treatment was not clear. There are several cases reported of patients with rheumatic diseases and, during follow-up, they were diagnosed with WD \[[@CR13], [@CR14], [@CR17], [@CR18]\]. Thus, the case report of a patient with an initial diagnosis of rheumatoid arthritis who developed pericarditis caused by WD (diagnosed by pericardial biopsy) and the patient who had not been treated previously with TNF-α blocker \[[@CR17]\].

In summary, anti-TNF-α treatment seems to increase the risk of exacerbation of WD and WD may mimic a rheumatic disease.

Consent {#Sec7}
=======

Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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